ALX Oncology to Present New Clinical Data on Evorpacept in Acute Myeloid Leukemia at 64th ASH Annual Meeting

On November 3, 2022 ALX Oncology Holdings Inc., ("ALX Oncology") (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, reported the Company will be presenting clinical data from the dose escalation portion of ASPEN-05, a Phase 1 study evaluating evorpacept in combination with azacitidine and venetoclax for the treatment of acute myeloid leukemia ("AML") at the 64th American Society of Hematology (ASH) (Free ASH Whitepaper) ("ASH") Annual Meeting held December 10-13, 2022 in New Orleans, Louisiana (Press release, ALX Oncology, NOV 3, 2022, View Source [SID1234622916]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The accepted abstract is listed below and is now available online on the ASH (Free ASH Whitepaper) website: View Source

Poster Presentation Details

Title: Evorpacept (ALX148), a CD47-Blocking Myeloid Checkpoint Inhibitor, in Combination with Azacitidine and Venetoclax in Patients with Acute Myeloid Leukemia (ASPEN-05): Results from Phase 1a Dose Escalation Part

Session Name: 616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster III

Presentation Date and Location: Monday, December 12, 2022, 6:00pm – 8:00pm CT, Ernest N. Morial Convention Center, Hall D

Publication Number: 4076